Novel sebum secretion inhibitory agent

Abstract

The present invention relates to a novel sebum secretion inhibitor and use thereof for the production of cosmetic and pharmaceutical, notably dermatological, compositions, intended for preventing and/or reducing the secretion of sebum and notably of squalene.

1 . Cosmetic use of an  Orthosiphon stamineus  extract for preventing and/or reducing and/or delaying the secretion of sebum, in particular of squalene. 
     
     
         2 . (canceled) 
     
     
         3 . Cosmetic use according to  claim 1  for the cosmetic care and/or treatment of skin described as normal, greasy, having a greasy tendency and/or mixed, and/or of hair described as greasy, and/or having a greasy tendency. 
     
     
         4 . Use of an  Orthosiphon stamineus  extract for preparing a pharmaceutical, notably dermatological composition intended for preventing and/or treating at least one pathology associated with hyperproduction of sebum, notably of squalene. 
     
     
         5 . Use according to  claim 4 , in which the pathology is selected from the pathological hyperseborrhoeas, seborrhoeic eczema, and/or hypersecretion in nursing infants, and/or any combination thereof. 
     
     
         6 . Use according to  claim 1  at a concentration between 1.10 −4 % and 10% by weight, and advantageously between 1.10 −4 % and 5% by weight of the total composition. 
     
     
         7 . Use according to one of the preceding claims  claim 1  at a concentration between 1.10 −3 % and 3% by weight of the total composition. 
     
     
         8 . Use according to one of the preceding claims  claim 1 , in which the  Orthosiphon stamineus  extract is obtained from leaves. 
     
     
         9 . Use according to one of the preceding claims  claim 1 , in which the  Orthosiphon stamineus  extract is obtained by hot aqueous extraction, notably by percolation between 30 and 50° C. 
     
     
         10 . Use according to  claim 1  by application to a surface of the body selected from the skin of the face, including the forehead, the cheeks and/or the chin, of the neck, of the back, of the thorax, of the hands, and/or of the chest. 
     
     
         11 . Cosmetic or pharmaceutical, notably dermatological composition comprising an  Orthosiphon stamineus  extract in combination with at least one agent selected from the seboregulating agents and/or at least one agent with a complementary property selected from exfoliating agents, keratolytic agents, agents stimulating the synthesis of fibronectin, agents protecting the fibroblast growth factor (FGF2), agents stimulating the growth of fibroblasts, an antibacterial agent, a sebum absorber, a comedolytic agent, a local antibiotic, and any mixture thereof. 
     
     
         12 . Composition according to  claim 11 , in which the  Orthosiphon stamineus  extract is contained at a concentration between 1.10 −4  and 10% by weight, and advantageously between 1.10 −4  and 5% by weight of the total composition. 
     
     
         13 . Composition according to  claim 12  at a concentration between 1.10 −3  and 3% by weight of the total composition. 
     
     
         14 . Composition according to  claim 11 , in which the  Orthosiphon stamineus  extract is obtained from leaves. 
     
     
         15 . Composition according to  claim 11 , in which the  Orthosiphon stamineus  extract is obtained by hot aqueous extraction, notably by percolation between 30 and 50° C. 
     
     
         16 . Composition according to  claim 11 , in which the seboregulating agent is selected from sarcosine, zinc salicylate, zinc gluconate, azelaic acid, and/or their derivatives and/or any mixture thereof. 
     
     
         17 . Composition according to  claim 11 , in which the agent with a complementary property is selected from AHA, a maize extract, an extract of  Hibiscus abelmoschus , a fermented soya extract containing peptides, a biotechnologically modified malt extract, a talc, an absorbent polymer, an extract of Boldo, retinoic acid or a derivative thereof, benzoyl peroxide, erythromycin, clindamycin phosphate and any mixture thereof 
     
     
         18 . Use of a cosmetic composition according to  claim 11 , for preventing and/or reducing and/or delaying the secretion of sebum, in particular of squalene and/or for preventing and/or reducing and/or delaying the dilatation of the pore size of the skin and/or the formation of blackheads and/or the shiny appearance of the skin and/or of the hair and/or comedogenesis. 
     
     
         19 . Pharmaceutical composition according to  claim 11  for preventing and/or treating at least one pathology associated with hyperproduction of sebum, notably of squalene, and especially pathological hyperseborrhoeas, seborrhoeic eczema and/or hypersecretion in nursing infants. 
     
     
         20 . Method of cosmetic care and/or treatment comprising the daily topical application of an  Orthosiphon stamineus  extract for preventing and/or reducing and/or delaying the secretion of sebum or of a composition according to  claim 11  for preventing and/or reducing and/or delaying the secretion of sebum, in particular of squalene and/or for preventing and/or reducing the unaesthetic and/or unpleasant and/or uncomfortable manifestations associated with the secretion of sebum, notably for preventing and/or reducing and/or delaying the dilatation of the pore size of the skin and/or the formation of blackheads and/or the shiny appearance of the skin and/or of the hair and/or comedogenesis. 
     
     
         21 . Method according to  claim 20 , in which daily topical application is carried out for at least 10 days, preferably for at least 20 days.